

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (currently amended) A method of treating pain or alcohol abuse in a patient, or providing opioid reversal therapy, or opioid maintenance therapy to a patient comprising administering a therapeutic amount of a drug condensation aerosol to the patient by inhalation, wherein the drug is selected from the group consisting of fentanyl, naltrexone, buprenorphine, naloxone, butorphanol, hydromorphone, oxycodone, methadone, remifentanyl and sufentanyl, and

wherein the condensation aerosol is formed by heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and condensing the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.

2. (previously presented) The method according to claim 1, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns.

3. (previously presented) The method according to claim 1, wherein peak plasma drug concentration is reached in less than 0.1 hours.

4. (cancelled)

5. (previously presented) The method according to claim 1, wherein the condensation aerosol is formed at a rate greater than 0.5 mg/second.

6. (original) The method according to claim 1, wherein at least 50% by weight of the condensation aerosol is amorphous in form.

7.-10. (cancelled)

11. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 0.01 mg and 0.8 mg of fentanyl delivered in a single inspiration.

12. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 15 mg and 35 mg of naltrexone delivered in a single inspiration.

13. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 0.1 mg and 1 mg of buprenorphine delivered in a single inspiration.

14. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 0.05 mg and 3.5 mg of naloxone delivered in a single inspiration.

15. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 0.1 mg and 3 mg of butorphanol delivered in a single inspiration.

16. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 0.1 mg and 10 mg of hydromorphone delivered in a single inspiration.

17. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 0.5 mg and 10 mg of oxycodone delivered in a single inspiration.

18. (previously presented) The method according to claim 1, wherein the therapeutic amount of a drug condensation aerosol comprises between 0.25 mg and 20 mg of methadone delivered in a single inspiration.

19. (previously presented) A method of administering a drug condensation aerosol to a patient comprising administering the drug condensation aerosol to the patient by inhalation, wherein the drug is selected from the group consisting of fentanyl, naltrexone, buprenorphine, naloxone, butorphanol, hydromorphone, oxycodone, methadone, remifentanyl and sufentanyl, and

wherein the drug condensation aerosol is formed by heating a thin layer containing the drug, on a solid support, to produce a vapor of the drug, and condensing the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns.

20. (cancelled)

21. (currently amended) A kit for delivering a drug condensation aerosol comprising:

a. a thin layer containing the drug, on a solid support, wherein the drug is selected from the group consisting of fentanyl, naltrexone, buprenorphine, naloxone, butorphanol, hydromorphone, oxycodone, methadone, remifentanyl and sufentanyl, and

b. a device for providing the condensation aerosol, wherein the condensation aerosol is formed by heating the thin layer to produce a vapor of the drug, and condensing the vapor to form a condensation aerosol characterized by less than 10% drug degradation products by weight, and an MMAD of less than 5 microns. ~~dispensing said thin coating as a condensation aerosol.~~

22. (cancelled)

23. (previously presented) The kit according to claim 21, wherein the device comprises:

a. a flow through enclosure containing the solid support,

b. a power source that can be activated to heat the solid support, and
c. at least one portal through which air can be drawn by inhalation,
wherein activation of the power source is effective to produce a vapor of the drug, and
drawing air through the enclosure is effective to condense the vapor to form the condensation
aerosol.

24. (previously presented) The kit according to claim 23, wherein the heat for heating
the solid support is generated by an exothermic chemical reaction.

25. (previously presented) The kit according to claim 24, wherein the exothermic
chemical reaction is oxidation of combustible materials.

26. (previously presented) The kit according to claim 23, wherein the heat for heating
the solid support is generated by passage of current through an electrical resistance element.

27. (previously presented) The kit according to claim 23, wherein the solid support
has a surface area dimensioned to accommodate a therapeutic dose of the drug.

28. (previously presented) The kit according to claim 21, wherein peak plasma drug
concentration is reached in less than 0.1 hours.

29. (previously presented) The kit according to claim 21, further including
instructions for use.

30. (previously presented) The method according to claim 1, wherein the
condensation aerosol is characterized by an MMAD of 0.2 to 5 microns.

31. (previously presented) The method according to claim 2, wherein the
condensation aerosol is characterized by an MMAD of 0.2 to 3 microns.

32. (previously presented) The method according to claim 19, wherein the drug is fentanyl.

33. (previously presented) The method according to claim 19, wherein the drug is naltrexone.

34. (previously presented) The method according to claim 19, wherein the drug is buprenorphine.

35. (previously presented) The method according to claim 19, wherein the drug is naloxone.

36. (previously presented) The method according to claim 19, wherein the drug is butorphanol.

37. (previously presented) The method according to claim 19, wherein the drug is hydromorphone.

38. (previously presented) The method according to claim 19, wherein the drug is oxycodone.

39. (previously presented) The method according to claim 19, wherein the drug is methadone.

40. (previously presented) The method according to claim 19, wherein the drug is remifentanyl.

41. (previously presented) The method according to claim 19, wherein the drug is sufentanyl.

42. (previously presented) The kit according to claim 21, wherein the condensation aerosol is characterized by an MMAD of less than 3 microns.
43. (previously presented) The kit according to claim 21 wherein the condensation aerosol is characterized by an MMAD of 0.2 to 5 microns.
44. (previously presented) The kit according to claim 42, wherein the condensation aerosol is characterized by an MMAD of 0.2 to 3 microns.
45. (previously presented) The kit according to claim 21, wherein the drug is fentanyl.
46. (previously presented) The kit according to claim 21, wherein the drug is naltrexone.
47. (previously presented) The kit according to claim 21, wherein the drug is buprenorphine.
48. (previously presented) The kit according to claim 21, wherein the drug is naloxone.
49. (previously presented) The kit according to claim 21, wherein the drug is butorphanol.
50. (previously presented) The kit according to claim 21, wherein the drug is hydromorphone.
51. (previously presented) The kit according to claim 21, wherein the drug is oxycodone.
52. (previously presented) The kit according to claim 21, wherein the drug is methadone.

53. (previously presented) The kit according to claim 21, wherein the drug is remifentanyl.

54. (previously presented) The kit according to claim 21, wherein the drug is sufentanyl.

55. (previously presented) The kit according to claim 23, wherein the solid support has a surface to mass ratio of greater than 1 cm² per gram.

56. (previously presented) The kit according to claim 23, wherein the solid support has a surface to volume ratio of greater than 100 per meter.

57. (previously presented) The kit according to claim 23, wherein the solid support is a metal foil.

58. (previously presented) The kit according to claim 57, wherein the metal foil has a thickness of less than 0.25 mm.